2.1B
People aged 60+ by 2050 — double today's figure
1.4B by 2030; the 80+ group triples to 426M by 2050.
World Health Organization, Ageing and healthOct 2025Confidence: A — primary source, public method, under 18 months old
Initial front
Longevity & prevention
Clinics, personalised protocols, prevention, early detection and an active later life. Healthspan — the years lived in good health — is the metric that matters, not lifespan alone.
What we look for
- Preventive clinics and protocols built on consolidated evidence, with measured outcomes
- Continuous diagnostic and follow-up models (tests, biomarkers, imaging) with a real service layer
- Services for an active later life: mobility, autonomy, community
- Models that widen access beyond the top income decile — this is where our thesis is tested
What stays out
- Drug discovery and geroscience biotech
- Anti-ageing aesthetics
- Protocols without a clinical evidence base or a plan to build one
What we do not claim
We do not claim that any protocol adds years of life or reverses biological age. Longevity today is for the few; our thesis depends on widening access, and that is what we will measure.
Data for this front
2070s
When people aged 65+ will outnumber children under 18 worldwide
1 in 6 people will be 65+ by 2050, versus 1 in 11 in 2019.
UN DESA, World Population Prospects 2024Jul 2024Confidence: A — primary source, public method, under 18 months old
US$ 8.5B
Investment in longevity companies in 2024, more than double 2023 — 84% of it in the United States
Single source, biotech-heavy scope. 2025 figures use a narrower definition and are not comparable.
Longevity.Technology, Annual Longevity Investment Report 2024May 2025Confidence: B — single reliable source, or a projection
Market signals
Market signals, not portfolio. Public examples of capital and demand in our verticals, each with source and date. None is a portfolio company, target or partner.
Neko Health SE
Longevity & preventionPreventive full-body scanning with continuous follow-up. Series C of US$ 700M at ~US$ 7B valuation.
TechCrunchJul 2026Confidence: A — primary source, public method, under 18 months old
Function Health US
Longevity & prevention160+ lab tests by subscription; acquired Ezra (whole-body MRI). Series B of US$ 298M at US$ 2.5B.
TechCrunchNov 2025Confidence: A — primary source, public method, under 18 months old
Beep Saúde BR
Longevity & preventionHome lab tests and vaccines, profitable. Raised R$ 100M at R$ 1.2B valuation (Lightsmith, CZI).
NeoFeedSep 2024Confidence: A — primary source, public method, under 18 months old
Other fronts